Advertisement

BMC Infectious Diseases

, 19:308 | Cite as

Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial

  • Clotilde El Guerche-SéblainEmail author
  • Annick Moureau
  • Camille Schiffler
  • Martin Dupuy
  • Stephanie Pepin
  • Sandrine I. Samson
  • Philippe Vanhems
  • François Schellevis
Open Access
Research article
Part of the following topical collections:
  1. Viral diseases

Abstract

Background

Despite World Health Organization recommendations, in many countries young children are not targeted for influenza vaccination. To help inform influenza vaccination policy, we examined the occurrence and burden of influenza in healthy children aged 6 to 35 months using data from a recent phase III placebo-controlled influenza vaccine trial conducted in countries in the Northern and Southern Hemispheres.

Methods

This was an analysis of data from participants included in the placebo arm of a phase III clinical trial in healthy children aged 6 to 35 months (EudraCT no. 2013–001231-51). Included children had never been vaccinated for influenza and were observed for one influenza season. Outcome measures included the occurrence of influenza-like illness (ILI), laboratory-confirmed influenza, virus types/subtypes, severe symptoms and complications of confirmed influenza, and healthcare use associated with confirmed influenza.

Results

Data from 2210 participants were analysed. ILI was reported for 811 participants (36.7%). Of these, 255 participants (31.4%) had 263 virologically confirmed episodes of influenza. The overall influenza attack rate was 11.5%. The most common influenza virus detected was A(H3N2) (40.7%), followed by B/Yamagata (23.6%), A(H1N1) (18.6%), and B/Victoria (8.0%). Grade 3 fever was reported in 24.3% of confirmed episodes, acute lower respiratory infection in 8.7%, acute otitis media in 6.1%, and pneumonia in 1.9%. In most influenza episodes (93.2%), antipyretics, analgesics, or non-steroidal anti-inflammatory drugs were taken. Antibiotics were prescribed for 41.4% of influenza episodes. More than half of the influenza episodes (57.0%) resulted in outpatient visits. Influenza resulted in overnight hospitalisation in 1.1% of episodes.

Conclusions

Influenza is associated with a significant burden of disease in healthy children. This analysis also revealed that antibiotics continue to be frequently used for young children with influenza.

Trial registration

EudraCT no. 2013–001231-51.

Keywords

Influenza Children Fever Hospitalisation Epidemiology Clinical trial Acute otitis media Acute lower respiratory infection Pneumonia Antibiotic use 

Abbreviations

AOM

Acute otitis media

ILI

Influenza-like illness

WHO

World Health Organization

Background

Influenza causes significant morbidity in young children and, each year, leads to hospitalisation of approximately 870,000 children under 5 years of age worldwide [1]. Whereas annual influenza attack rates range from 5 to 10% in adults, they range from 20 to 30% in children [2]. Young children are also important vectors for the spread of influenza in the community and within families because they are in close contact with each other in schools and day care, have close contact with adults and the elderly, have poor hygiene habits, have limited pre-existing immunity, and shed high virus titres [3].

The World Health Organization (WHO) recommends that children 6 to 59 months of age be considered a priority for influenza vaccination, along with pregnant women, elderly adults, individuals with specific chronic medical conditions, and healthcare workers [4]. Despite these recommendations, many countries do not have vaccination policies, and those that do often do not include young children as a target group [5]. This may be because severe influenza has been thought to be a problem limited to children with underlying high-risk conditions [6]. More information about the burden of influenza in young children is therefore needed to inform and support influenza vaccination policies.

A recent phase III placebo-controlled clinical trial conducted in several countries in the Northern and Southern Hemispheres examined the efficacy, immunogenicity, and safety of an inactivated quadrivalent influenza vaccine in healthy children aged 6 to 35 months [7]. To provide additional understanding of the occurrence and burden of influenza in healthy young children, we examined data collected from participants randomised to the placebo arm of the trial. This analysis focused on the occurrence of laboratory-confirmed influenza, the virus types/subtypes, severe symptoms and complications of influenza, and influenza-related healthcare use.

Methods

Study design

This was an analysis of data from participants included in the placebo arm of a phase III randomised controlled clinical trial (EudraCT no. 2013–001231-51; registered March 13, 2014) [7]. The participant flow diagram for the original study is provided in Additional file 1: Figure S1. Participants were included during the 2014 influenza season in South Africa, the 2014 and 2015 influenza seasons in the Philippines, the 2014/2015 influenza season in Honduras and the Dominican Republic, and the 2014/2015 and 2015/2016 influenza seasons in France, Greece, Italy, Spain, and Romania. Healthy children aged 6 to 35 months with no history of influenza vaccination were randomised to receive two placebo injections or two full doses 28 days apart of quadrivalent split-virion inactivated influenza vaccine, the licensed trivalent split-virion inactivated vaccine, or an investigational trivalent influenza vaccine that had the recommended B strain replaced with one from the other of the two influenza B lineages.

The primary endpoints for the current analysis were the occurrence of an influenza-like illness (ILI) and the occurrence of laboratory-confirmed influenza by virus type/subtype. Other endpoints for this analysis included the occurrence of acute otitis media (AOM), acute lower respiratory infection, outpatient visits, inpatient hospitalisation, grade 3 fever, and grade 3 ILI symptoms. ILI, laboratory-confirmed influenza, and influenza virus subtypes were assessed as described previously [7]. Participants were considered to have ILI if they had a fever ≥38 °C lasting ≥24 h concurrently with cough, nasal congestion, rhinorrhoea, pharyngitis, otitis, vomiting, or diarrhoea. For subjects aged < 24 months, grade 1 fever was defined as a temperature ≥ 38.0 °C to ≤38.5 °C, grade 2 fever as > 38.5 °C to ≤39.5 °C, and grade 3 fever as > 39.5 °C [7]. For subjects aged ≥24 months, grade 1 fever was defined as a temperature ≥ 38.0 °C to ≤38.4 °C, grade 2 as ≥38.5 °C to ≤38.9 °C, and grade 3 as > 39.0 °C. ILI symptoms were considered grade 1 if they did not interfere with daily activity, grade 2 if they caused some interference with daily activity, and grade 3 if they were significant and prevented daily activity.

Temperature and ILI symptoms were recorded by parents or legal representatives on diary cards. From 14 days after the second placebo injection until the end of the influenza season, parents or legal representatives of participants were instructed to contact their study site within 24 h if their child experienced ILI symptoms. In addition, during the peak of the influenza season, investigators contacted the parents or legal representatives of participants twice each week by phone to ask about possible ILI symptoms. If ILI was suspected during a phone call, the investigator systematically collected information on symptoms and healthcare utilisation and arranged for the participant to visit the study site within 10 days of ILI onset. For all suspected ILIs, information on ILI symptoms and healthcare utilisation were updated through follow-up phone calls scheduled 15 days after onset and subsequently every 30 days until full recovery from ILI. In the arranged visits for suspected ILI, a nasopharyngeal swab was taken for laboratory confirmation of influenza by both viral culture and reverse transcription polymerase chain reaction. Sanger sequencing of the hemagglutinin and neuraminidase full-gene segments was performed to identify the specific type or subtype of influenza. Healthcare utilisation and the presence of AOM and acute lower respiratory infection were also recorded during the visit. For healthcare utilisation, inpatient hospitalisation was defined as a hospital admission resulting in an overnight stay, and an outpatient visit was defined as an unscheduled ambulatory visit with a physician or other healthcare professional without overnight stay. AOM was defined as a visually abnormal tympanic membrane suggesting an effusion in the middle ear cavity concomitant with one or more of the following symptoms: fever (≥ 38 °C), earache, irritability, diarrhoea, vomiting, acute otorrhoea not caused by external otitis, or other symptoms of a respiratory infection. Acute lower respiratory infection was defined as radiologically confirmed pneumonia, bronchiolitis, bronchitis, or laryngotracheobronchitis [7, 8].

Statistical analysis

Statistical analyses were descriptive only and were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA). Attack rates were calculated using the number of influenza positive cases, with the denominator as the number of included patients in the placebo arm. This corresponds to the incidence per influenza season. The 95% confidence intervals of the attack rates were calculated using a normal approximation. Occurrence of grade 3 symptoms, complications, and healthcare use were calculated using confirmed influenza episodes as the denominator.

Results

Participants

This analysis included 2210 of the 2591 participants randomised in the placebo arm of the trial who completed the two-dose vaccination schedule and had at least one contact during follow-up (1469 from the Philippines, 502 from the included European countries, and 239 from South Africa) [7]. Participants from Honduras and the Dominican Republic (n = 379) were excluded from this analysis because they had been included outside of the influenza season, resulting in no influenza cases detected [7]. Two participants randomised to the placebo arm were excluded from this analysis because they had accidentally received one dose of influenza vaccine instead of placebo. The overall mean age was 19.9 months, and mean ages were similar in each region (Table 1). Overall, the male/female ratio was 1.1, and more boys than girls were included in all regions.
Table 1

Characteristics of participants included in the analysis

 

South Africa

Philippines

European countries a

Overall

Characteristic

N = 239

N = 1469

N = 502

N = 2210

Male/female ratio

1.37

1.05

1.03

1.10

Age (months), mean ± standard deviation

19.7 ± 7.9

19.9 ± 8.6

20.0 ± 8.2

19.9 ± 8.4

aFrance, Greece, Italy, Spain, and Romania

ILI and laboratory-confirmed influenza

ILI was reported by 811 (36.7%) of the 2210 participants (Table 2). Of these, 255 participants had 263 virologically confirmed episodes of influenza. The influenza attack rate was more than two times higher in the European countries (20.5%) than in South Africa (6.7%) and the Philippines (9.3%). The overall influenza attack rate was 11.5%.
Table 2

Proportion of participants with influenza-like illness and laboratory-confirmed influenza, and influenza attack rates

 

South Africa

Philippines

European countries a

Overall

Measure

N = 239

N = 1469

N = 502

N = 2210

Influenza-like illness, n (%) b

45 (18.8)

510 (34.7)

256 (51.0)

811 (36.7)

Laboratory-confirmed influenza, n (%) c

16 (35.6)

136 (26.7)

103 (40.2)

255 (31.4)

Influenza attack rate, % (95% CI) b

6.7 (3.5; 9.9)

9.3 (7.8; 10.7)

20.5 (17.0; 24.1)

11.5 (10.2; 12.9)

Abbreviations: CI, confidence interval

aFrance, Greece, Italy, Spain, and Romania

bPercentage of all participants

cPercentage of participants with influenza-like illness

The most common serotype was A(H3N2) (40.7% of confirmed episodes), followed by B/Yamagata (23.6%) and A(H1N1) (18.6%). Relatively few episodes of B/Victoria infection were reported (8.0%) (Table 3). Attack rates were 2.2% for A(H1N1), 4.6% for A(H3N2), 2.8% for B/Yamagata and 1.0% for B/Victoria. By region and season, A(H3N2) was the most frequently detected influenza subtype during the 2014 season in South Africa, the 2015 season in the Philippines, and the 2014/2015 season in the included European countries, whereas B/Yamagata was the most frequently detected subtype during the 2014 season in the Philippines and A(H1N1) was the most frequently detected during the 2015/2016 season in the European countries.
Table 3

Circulation of influenza strains by region and season and attack rates

Subtype/ lineage

Confirmed influenza episodes, n (%)

 

South Africa 2014

Philippines 2014

Philippines 2015

European countries a 2014/2015

European countries a 2015/2016

Total

N = 17

N = 93

N = 45

N = 37

N = 71

N = 263

Attack rate b, % (95% CI)

A(H1N1)

 0 (0.0)

 0 (0.0)

 2 (4.4)

 2 (5.4)

 45 (63.4)

 49 (18.6)

 2.2 (1.6; 2.8)

A(H3N2)

 16 (94.1)

 23 (24.7)

 43 (95.6)

 24 (64.9)

 1 (1.4)

 107c (40.7)

 4.6 (3.7; 5.5)

B/Yamagata

 1 (5.9)

 53 (57.0)

 0 (0.0)

 8 (21.6)

 0 (0.0)

 62 (23.6)

 2.8 (2.1; 3.5)

B/Victoria

 0 (0.0)

 0 (0.0)

 0 (0.0)

 0 (0.0)

 21 (26.9)

 21 (8.0)

 1.0 (0.5; 1.4)

Not subtyped

 0 (0.0)

 17 (18.3)

 0 (0.0)

 3 (8.1)

 4 (5.6)

 24 (9.1)

 1.1 (0.7; 1.5)

aFrance, Greece, Italy, Spain, and Romania

bCalculated as the number of participants with at least one episode of confirmed influenza divided by the total number of participants (N = 2210)

c107 episodes in 102 participants

Burden of influenza

Grade 3 fever was reported for about one-quarter (24.3%) of the 263 confirmed influenza episodes (Table 4). Less than 10% of the confirmed influenza episodes were associated with acute lower respiratory infection (8.7%) or AOM (6.1%). Influenza was associated with pneumonia in 1.9% of the confirmed episodes.
Table 4

Occurrence of grade 3 symptoms, complications, and healthcare use associated with confirmed influenza episodes

 

Confirmed influenza episodes

Proportion of episodes

Laboratory-confirmed influenza associated with:

N = 263

(%)

Grade 3 symptoms

 

 Grade 3 fever a

63

24.3

 ≥ 1 grade 3 influenza-like illness symptom b

8

3.0

Complications

 

 Acute otitis media

16

6.1

 Acute lower respiratory infection

23

8.7

 Pneumonia

5

1.9

Medication

 

 Any

257

97.7

Antibiotics

109

41.4

 Antipyretic or analgesic medication c

245

93.2

 Antitussives

8

3.0

 Bronchodilators

36

13.7

 Expectorants

10

3.8

 Mucolytic agents

47

17.9

Healthcare use

 

 Outpatient visit

150

57.0

 Inpatient hospitalisation

3

1.1

 Intensive care unit admission

0

0.0

a> 39.5 °C for subjects aged < 24 months and ≥ 39.0 °C for subjects aged ≥24 months

bCough, nasal congestion, rhinorrhoea, pharyngitis, otitis, vomiting, or diarrhoea preventing daily activities

cIncludes non-steroidal anti-inflammatory drugs

Participants received medication during nearly all confirmed influenza episodes (97.7%). For 93.2% of confirmed influenza episodes, antipyretic or analgesic medication was taken. For 41.4% of the confirmed influenza episodes, antibiotics were prescribed and taken. Antipyretic or analgesic medication, antitussives, bronchodilators, expectorants, and mucolytic agents were each prescribed in fewer than 20% of the confirmed influenza episodes. Medication use by region is described in Additional file 2: Table S1.

More than half of the confirmed influenza episodes (57.0%) resulted in one or more outpatient visits. Few episodes resulted in overnight hospitalisation (n = 3; 1.1%). No children with confirmed influenza were admitted to an intensive care unit.

Discussion

Although the WHO recommends including young children as a target group for influenza vaccination, many countries do not include them in their recommendations [5], probably because severe influenza has not been considered a problem for children without underlying high-risk conditions [6]. In this study we showed that 11.5% of 2210 healthy unvaccinated children 6 to 35 months of age contracted influenza during the influenza season. In many of these children, infection with influenza virus resulted in high fever, complications, medical visits, and use of antibiotics.

We found that more than one-third of influenza episodes were associated with grade 3 fever. AOM, also common in cases of influenza [9], was reported for 6.1% of influenza episodes. This is lower than that found in another study of children aged < 3 years (39.7%) [10] but close to rates reported in studies of children aged < 2 years (6.4%) and 2 to 4 years (4.9%) [11]. Acute lower respiratory infections were documented for 8.7% of influenza episodes, which is lower than the combined rate of 13% for children < 5 years of age reported in a meta-analysis by Nair et al. [12]. Finally, influenza was associated with pneumonia in just under 2% of episodes.

The rates of medication use, outpatient visits, and hospitalisations in the study generally agreed with a systematic review by Antonova et al. [3] who reported that 76 to 99% of children aged < 18 years with laboratory-confirmed influenza received antipyretic or other medications for symptomatic relief and that 0.3 to 20% were hospitalised. Importantly, antibiotics were prescribed for more than 40% of the confirmed influenza episodes. A few of these antibiotic prescriptions could have been for influenza-associated AOM or acute lower respiratory infection, which were observed in 15% of influenza cases. We did not find other reports describing antibiotic use in young children with ILI, although the systematic review by Antonova et al. reported that influenza is associated with antibiotic prescriptions in 7 to 55% of cases in European children aged < 18 years [3]. A retrospective analysis of the US Impact National Benchmark Database from 2005 to 2009 found that antibiotics were prescribed in about 22% of all patients with influenza and were used inappropriately in 79% of the cases because of an absence of secondary infection or comorbidity [13]. Thus, unnecessary antibiotic use in influenza appears to be a continuing problem and may be contributing to the spread of antibiotic-resistant bacteria [13, 14].

Strain circulation differed between consecutive seasons in the same region. For example, in the included European countries, A(H3N2) dominated during the 2014/2015 influenza season and A(H1N1) dominated during the 2015/2016 season. In the Philippines, B/Yamagata dominated during the 2014 season, whereas A(H3N2) dominated during the 2015 season. In both seasons in the European countries, the B lineage recommended by the WHO for the trivalent vaccine [15, 16] did not match with the dominant circulating B lineage. Although the study included relatively few confirmed influenza episodes, strain circulation in this study population generally agreed with the WHO seasonal reports [15, 16, 17, 18].

A unique characteristic of our analysis is that the data resulted from active surveillance during a randomised, placebo-controlled vaccine efficacy trial. This favours systematic and complete data collection, and therefore would have reduced the chance of missing ILI episodes. Although active surveillance could have increased the rate of ILI compared to passive surveillance, the overall influenza attack rate (11.5%) was consistent with the rate described in a 2014 meta-analysis (15.2% [95% confidence interval, 11.4 to 18.9]) for unvaccinated children aged < 18 years [19]. However, this overall attack rate is substantially lower than that described by the WHO (20 to 30% for children) [2]. Similarly, the higher attack rate in the European countries (20.5%) compared to the other countries (6.7%–9.3%) cannot be explained by the surveillance procedures used to identify ILI cases, since these were identical in all participating countries. The burden of influenza between countries can vary widely and is determined by a number of factors including the characteristics of circulating viruses, and the timing and severity of the season [4]. Our study included countries located in different regions with different latitudes, climates, and influenza seasonality that may partly explain the differences between the influenza attack rates observed. For example, in Europe, the 2014–2015 season was particularly severe [20], which could partly explain the higher attack rate reported compared to other regions.

An important limitation of this analysis is that the population was selected for the phase III clinical trial and may not have been representative of the wider population in the included regions. Specifically, the trial included children without comorbidities who were presumed to be immunologically naïve to influenza. The inclusion of only children without comorbidities may explain why the attack rate was lower in this analysis than reported by the WHO [2] and in the 2014 meta-analysis [19].

A final limitation is that Honduras and the Dominican Republic were not included in this analysis because participants in this region had been recruited outside the influenza season – which is often difficult to define in the tropics and subtropics [21] – resulting in no confirmed influenza cases.

Conclusions

With data available from the placebo arm of a large clinical trial [7], we confirmed that healthy young children are susceptible to influenza and that, in many cases, influenza infection in young children is associated with severe symptoms, frequent healthcare use, and inappropriate antibiotic use. These findings should support efforts to enact recommendations by the WHO to include young children in national influenza vaccination policies.

Notes

Acknowledgements

Medical writing was provided by Dr. Phillip Leventhal (4Clinics, France).

Funding

Funding for this analysis and for medical writing was provided by Sanofi Pasteur.

Availability of data and materials

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymised and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi’s data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com.

Authors’ contributions

C.E.S., P.V., and F.S. conceived of and designed the study. A.M., M.D., and S.P. acquired data. C.E.S., A.M., C.S., S.S., P.V., and F.S. analysed and interpreted data. C.E.S., C.S., M.D., and F.S. participated in drafting the article. All authors provided critical comments or revisions, approved the final version of the article, and agree to be accountable for its accuracy and integrity.

Ethics approval and consent to participate

The study was approved by the independent ethics committee or institutional review board for each study site (full details provided in Additional File 3) and was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was provided by the parents or legal representatives of all children participating in this trial.

Consent for publication

Not applicable.

Competing interests

C.E.S., A.M., C.S., M.D., S.P., and S.S. are employees of Sanofi Pasteur. F.S. and P.V. declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary material

12879_2019_3920_MOESM1_ESM.pdf (13 kb)
Additional file 1: Figure S1. Participant flow diagram for the original study (PDF 12 kb)
12879_2019_3920_MOESM2_ESM.pdf (9 kb)
Additional file 2: Table S1. Medication use associated with confirmed influenza episodes by region (PDF 8 kb)
12879_2019_3920_MOESM3_ESM.pdf (140 kb)
Additional file 3 Ethics Committees that approved the original study (PDF 139 kb)

References

  1. 1.
    Lafond KE, Nair H, Rasooly MH, Valente F, Booy R, Rahman M, et al. Global role and burden of influenza in poediatric respiratory hospitalizations, 1982-2012: a systematic analysis. PLoS Med. 2016;13(3):e1001977.CrossRefGoogle Scholar
  2. 2.
    World Health Organization. Influenza. WHO. http://www.who.int/biologicals/vaccines/influenza/en/ (2017). Accessed 7 Dec 2017.
  3. 3.
    Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N. Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health. 2012;12:968.CrossRefGoogle Scholar
  4. 4.
    World Health Organization. Influenza (seasonal). WHO. 2018. https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal). Accessed 5 Jan 2019.
  5. 5.
    Ortiz JR, Perut M, Dumolard L, Wijesinghe PR, Jorgensen P, Ropero AM, et al. A global review of national influenza immunization policies: analysis of the 2014 WHO/UNICEF joint reporting form on immunization. Vaccine. 2016;34(45):5400–5.CrossRefGoogle Scholar
  6. 6.
    Principi N, Esposito S. Protection of children against influenza: emerging problems. Hum Vaccin Immunother. 2018;14(3):750–7.CrossRefGoogle Scholar
  7. 7.
    Pepin S, Dupuy M, Corazon Tabora CF, Montellano M, Bravo L, Cadorna-Carlos J, et al: Intramuscular quadrivalent influenza vaccine is efficacious in naive children aged 6 to 35 months: A large-scale, placebo-controlled trial. ESP17–1082. In: European Society for Paediatric Infectious Diseases. Madrid, Spain; 2017.Google Scholar
  8. 8.
    Malosh RE, Martin ET, Ortiz JR, Monto AS. The risk of lower respiratory tract infection following influenza virus infection: a systematic and narrative review. Vaccine. 2018;36(1):141–7.CrossRefGoogle Scholar
  9. 9.
    Nokso-Koivisto J, Marom T, Chonmaitree T. Importance of viruses in acute otitis media. Curr Opin Pediatr. 2015;27(1):110–5.CrossRefGoogle Scholar
  10. 10.
    Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190(8):1369–73.CrossRefGoogle Scholar
  11. 11.
    Matias G, Haguinet F, Lustig RL, Edelman L, Chowell G, Taylor RJ. Model estimates of the burden of outpatient visits attributable to influenza in the United States. BMC Infect Dis. 2016;16(1):641.CrossRefGoogle Scholar
  12. 12.
    Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–30.CrossRefGoogle Scholar
  13. 13.
    Misurski DA, Lipson DA, Changolkar AK. Inappropriate antibiotic prescribing in managed care subjects with influenza. Am J Manag Care. 2011;17(9):601–8.PubMedGoogle Scholar
  14. 14.
    Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342(4):225–31.CrossRefGoogle Scholar
  15. 15.
    World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. Wkly Epidemiol Rec. 2015;90(11):97–108.Google Scholar
  16. 16.
    World Health Organization. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Wkly Epidemiol Rec. 2014;89(10):93–104.Google Scholar
  17. 17.
    World Health Organization. Review of the 2014 influenza season in the southern hemisphere. Wkly Epidemiol Rec. 2014;89(48):529–41.Google Scholar
  18. 18.
    World Health Organization. Review of the 2015 influenza season in the southern hemisphere. Wkly Epidemiol Rec. 2015;90(48):645–60.Google Scholar
  19. 19.
    Jayasundara K, Soobiah C, Thommes E, Tricco AC, Chit A. Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infect Dis. 2014;14:670.CrossRefGoogle Scholar
  20. 20.
    European Centre for Disease Prev Control Seasonal influenza - Annual Epidemiological Report: season 2014–2015. https://ecdc.europa.eu/sites/portal/files/documents/aer-seasonal_influenza_0.pdf (2015). Accessed 5 Jan 2019.
  21. 21.
    Hirve S, Newman LP, Paget J, Azziz-Baumgartner E, Fitzner J, Bhat N, et al. Influenza seasonality in the tropics and subtropics - when to vaccinate? PLoS One. 2016;11(4):e0153003.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Clotilde El Guerche-Séblain
    • 1
    Email author
  • Annick Moureau
    • 2
  • Camille Schiffler
    • 3
  • Martin Dupuy
    • 4
  • Stephanie Pepin
    • 5
  • Sandrine I. Samson
    • 6
  • Philippe Vanhems
    • 7
  • François Schellevis
    • 8
    • 9
  1. 1.Global Vaccine and Epidemiology DepartmentSanofi PasteurLyonFrance
  2. 2.Global Clinical Biostatistics DepartmentSanofi PasteurMarcy l’ÉtoileFrance
  3. 3.Global HEOR DepartmentSanofi PasteurLyonFrance
  4. 4.Global Biostatistics DepartmentSanofi PasteurMarcy l’ÉtoileFrance
  5. 5.Global Clinical Sciences, Sanofi PasteurMarcy l’ÉtoileFrance
  6. 6.Global Medical AffairsSanofi PasteurLyonFrance
  7. 7.Epidemiology and International Health Team, Emergent Pathogens Laboratory, Fondation Mérieux, International Center for Research in Infectiology, National Institute of Health and Medical Research, U1111, National Center of Scientific Research, Mixed Scientific Unit 5308, École Nationale Supérieure de LyonUniversité Claude Bernard Lyon 1LyonFrance
  8. 8.Netherlands Institute for Health Services ResearchUtrechtThe Netherlands
  9. 9.Department of General Practice & Elderly Care Medicine, Amsterdam Public Health Research InstituteAmsterdam University Medical CentresAmsterdamThe Netherlands

Personalised recommendations